URSa-1: A Minibasket Study of Pembrolizumab in Ultra-Rare Sarcomas
Memorial Sloan Kettering Cancer Center
Summary
The purpose of the study is to find out if pembrolizumab is a useful treatment that causes few or mild side effects in people with ultra-rare sarcoma. The researchers will also study how the immune system responds to the study treatment. Pembrolizumab is a type of drug called a PD-1 inhibitor. It is designed to block a protein called programmed cell death protein 1 (PD-1) that usually acts as a "brake" on the immune system. Blocking this protein is like releasing the brakes, so that the immune system can target cancer cells and destroy them.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion: * Patients must have pathologically confirmed diagnosis of one of the following: 1. Pleomorphic liposarcoma 2. PEComa (perivascular epithelial cell tumor) 3. Epithelioid sarcoma 4. CIC-rearranged sarcoma 5. SEF/LGFMS: Sclerosing epithelioid fibrosarcoma - low grade fibromyxoid sarcoma * Molecular characterization of the tumor, if available, will be recorded. If no such molecular data are available, note as such. * Patient should have recurrent or metastatic disease not judged to be curable with other means * Patients must have progressed (in the opinion of the treating i…
Interventions
- DrugPembrolizumab
Q 6 weeks IV infusion Day 1 of each 6-week cycle, up to 8 doses
Locations (6)
- Memorial Sloan Kettering at Basking Ridge (All Protocol Activities)Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities)Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Limited Protocol Activities)Montvale, New Jersey
- Memorial Sloan Kettering Cancer Center Suffolk- Commack (Limited Protocol Activities)Commack, New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activities)New York, New York
- Memorial Sloan Kettering Nassau (All Protocol Activities)Uniondale, New York